Рет қаралды 353,980
Boom in psychedelic therapies?
www.telegraph....
www.theguardia...
Short-acting drugs, psychedelic experience, two-hour therapy session.
Resetting brain networks
Helping to end ingrained negative patterns of thought,
and making patients far more receptive to therapy.
Small Pharma
smallpharma.com
Leading the world’s first regulated clinical trial,
DMT (dimethyltryptamine) with psychotherapy for major depressive disorder.
Phase one done on healthy volunteers
Next few months, reports from 42 patients
Dr Carol Routledge, chief medical and scientific officer
We think that this treatment will really get to the root cause, rather than just dampening symptoms
Almost immediate benefits
Based on initial data that we already have, and other companies have, there’s going to be a fairly immediate impact
In terms of the psychedelic experience, we’re talking about 20 minutes,
and then the integration therapy afterwards,
we expect the antidepressant activity to be extremely durable … to last maybe three, four or five months
Imaging data
Psychedelics work on the brain networks
Making neural connections more flexible to brain plasticity
You can reset those networks in the brain, and then that leaves the brain much more receptive to therapy, which is why we bring it in straight afterwards
Medicines and Healthcare products Regulatory Agency (MHRA)
Innovative Licensing and Access Pathway (ILAP)
Brings organisations together
Speed up the time getting meds to patients
Other companies testing MDMA
3,4-Methylenedioxymethamphetamine
Therapy for post-traumatic stress disorder (PTSD)
Psilocybin, (Clerkenwell Health)
Depression
Smoking
Terminal illness
Psychedelic experience
Out-of-body sensations
Visual or aural hallucinations
Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls
www.nature.com...
University of British Columbia, Vancouver, July, 2022
Psilocybin microdosing
Repeated self-administration of mushrooms containing psilocybin,
at doses small enough to not impact regular functioning.
3-5 times per week, of 0.1 to 0.3 g of dried mushrooms
Naturalistic, observational design
Study approved, University of British Columbia Research Ethics Board (H19-03051)
Psilocybin microdosers (n = 953)
Non-microdosing comparators (n = 180)
For approximately 30 days
Identified small- to medium-sized improvements in mood and mental health,
that were generally consistent across gender, age and presence of mental health concerns
Improved psychomotor performance in older adults.
Depression, Anxiety and Stress Scale
proceduresonli...
Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers
www.nature.com...
Large international sample of adults
microdosers (n = 4050)
non-microdosers (n = 4653)
Psilocybin, 85% of microdosers, (LSD, 11%)
microdosers exhibited lower levels of depression, anxiety, and stress across gender
microdosers were less likely to use alcohol regularly and were more likely to abstain from alcohol entirely
microdosers were more likely to abstain from the use of nicotine
Psilocybin, in 10mg or 25mg doses, has no short- or long-term detrimental effects in healthy people
www.kcl.ac.uk/...
journals.sagep...
The therapeutic potential of microdosing psychedelics in depression
www.ncbi.nlm.n...
Micro dose, 5% to 10% of psychotropic dose
LSD (10-20 mcg)
Psilocybin (less than 1-3 mg),
have subtle (positive) effects on cognitive processes (time perception, convergent and divergent thinking) and brain regions involved in affective processes.